title: Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
abstract: OBJECTIVE
  To evaluate the efficacy of a single intravitreal injection of ocriplasmin 125 μg across relevant subpopulations of patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT), including when associated with macular hole.
  
  
  METHODS
  Two multicenter, randomized, placebo-controlled, double-masked, 6-month studies.
  
  
  METHODS
  A total of 652 randomized patients (464 receiving ocriplasmin; 188 receiving placebo).
  
  
  METHODS
  A single intravitreal injection of ocriplasmin 125 μg or placebo in the study eye.
  
  
  METHODS
  Prespecified subgroup analyses were conducted to evaluate the effects on the proportion of patients with nonsurgical resolution of focal VMA at day 28, nonsurgical full-thickness macular hole (FTMH) closure at month 6, and categoric improvement in best-corrected visual acuity (BCVA) at month 6.
  
  
  RESULTS
  Resolution of VMA at day 28 was achieved more often in younger patients (<65 years), eyes without epiretinal membrane, eyes with FTMH, phakic eyes, and eyes with a focal VMA ≤ 1500 μm. Eyes with FTMH width ≤ 250 μm were more likely to achieve nonsurgical FTMH closure. Categoric ≥ 2-line and ≥ 3-line improvement in BCVA occurred more often in younger patients (<65 years) and in patients with a lower baseline BCVA (<65 letters). Treatment differences in favor of ocriplasmin were generally observed across each subgroup of subpopulations studied.
  
  
  CONCLUSIONS
  Subgroup analyses confirmed the positive effect of ocriplasmin across relevant subpopulations.
authors.affiliation: Wills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: jhaller@willseye.org.
authors.forename: Julia A
authors.initials: JA
authors.lastname: Haller
authors.affiliation: Department of Ophthalmology, UZ Leuven, Leuven, Belgium.
authors.forename: Peter
authors.initials: P
authors.lastname: Stalmans
authors.affiliation: Retina Consultants of Houston, Houston, Texas.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Benz
authors.affiliation: Department of Ophthalmology, Klinikum der LMU, Munich, Germany and MVZ, Memmingen, Munich, Germany.
authors.forename: Arnd
authors.initials: A
authors.lastname: Gandorfer
authors.affiliation: Amakem NV, Diepenbeek, Belgium (formerly of ThromboGenics NV).
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Pakola
authors.affiliation: NightstaRx Ltd, London, UK (formerly of ThromboGenics NV).
authors.forename: Aniz
authors.initials: A
authors.lastname: Girach
authors.affiliation: Department of Ophthalmology, Klinikum der LMU, Munich, Germany.
authors.forename: Anselm
authors.initials: A
authors.lastname: Kampik
authors.affiliation: Duke Reading Center, Duke University School of Medicine, Durham, North Carolina.
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Jaffe
authors.affiliation: Duke Reading Center, Duke University School of Medicine, Durham, North Carolina.
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Toth
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005128:Eye Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D022001:Focal Adhesions / Q000187:drug effects*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology; D055815:Young Adult
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin